Pyxis Oncology (PYXS) Change in Accured Expenses (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Change in Accured Expenses data on file, last reported at $552000.0 in Q4 2025.

• Change in Accured Expenses for Q4 2025 came in at $552000.0, up 120.54% year-over-year; the trailing twelve-month figure through Dec 2025 was -$2.8 million (down 69.04% YoY), and the FY2025 annual result was -$2.8 million, down 69.04% from the prior year.
• Change in Accured Expenses fell to $552000.0 in Q4 2025 per PYXS's latest filing, from $1.3 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $10.5 million in Q1 2022 and troughed at -$13.3 million in Q1 2023.
• A 5-year average of -$77350.0 and a median of $464500.0 in 2021 frame the typical range for Change in Accured Expenses.
• On a YoY basis, Change in Accured Expenses climbed as much as 2246.64% in 2022 and fell as far as 2762.07% in 2022.
• A 5-year view of Change in Accured Expenses shows it stood at $1.9 million in 2021, then surged by 227.54% to $6.3 million in 2022, then tumbled by 157.99% to -$3.7 million in 2023, then gained by 26.62% to -$2.7 million in 2024, then surged by 120.54% to $552000.0 in 2025.
• Business Quant data shows PYXS's Change in Accured Expenses at $552000.0 in Q4 2025, $1.3 million in Q3 2025, and -$3.4 million in Q2 2025.